Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery
Open Angle Glaucoma
About this trial
This is an interventional treatment trial for Open Angle Glaucoma focused on measuring ologen, collagen matrix, glaucoma, trabeculectomy, Mitomycin-C
Eligibility Criteria
Inclusion Criteria:
- Open angle glaucoma
- Maxima anti-glaucoma medication failed
- Age>18
- Able to complete the follow up
Exclusion Criteria:
- Topical eye inflammation
- Angle closure glaucoma
- Deformity glaucoma
- One eye glaucoma
- Previous conjunctiva opened
- Allergy to collagen
Sites / Locations
- Hospital of Universität Köln
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
MITOMYCIN-C
ologen (Oculusgen)
Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.
20 patients will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with ologen implant. The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.